Logo do repositório
 
A carregar...
Miniatura
Publicação

Helicobacter pylori Infection in Pediatric Patients Living in Europe: Results of the EuroPedHP Registry 2013 to 2016

Utilize este identificador para referenciar este registo.
Nome:Descrição:Tamanho:Formato: 
Helicobacter_pylori_Infection_in_Pediatric.12.pdf199.47 KBAdobe PDF Ver/Abrir

Orientador(es)

Resumo(s)

Objectives: The aim of the study was to assess clinical presentation, endoscopic findings, antibiotic susceptibility and treatment success of Helicobacter pylori (H. pylori) infected pediatric patients. Methods: Between 2013 and 2016, 23 pediatric hospitals from 17 countries prospectively submitted data on consecutive H. pylori-infected (culture positive) patients to the EuroPedHP-Registry. Results: Of 1333 patients recruited (55.1% girls, median age 12.6 years), 1168 (87.6%) were therapy naïve (group A) and 165 (12.4%) had failed treatment (group B). Patients resided in North/Western (29.6%), Southern (34.1%) and Eastern Europe (23.0%), or Israel/Turkey (13.4%). Main indications for endoscopy were abdominal pain or dyspepsia (81.2%, 1078/1328). Antral nodularity was reported in 77.8% (1031/1326) of patients, gastric or duodenal ulcers and erosions in 5.1% and 12.8%, respectively. Primary resistance to clarithromycin (CLA) and metronidazole (MET) occurred in 25% and 21%, respectively, and increased after failed therapy. Bacterial strains were fully susceptible in 60.5% of group A, but in only 27.4% of group B. Primary CLA resistance was higher in Southern and Eastern Europe (adjusted odds ratio [ORadj] = 3.44, 95% confidence interval [CI] 2.22–5.32, P < 0.001 and 2.62, 95% CI: 1.63–4.22, P < 0.001, respectively) compared with Northern/Western Europe. Children born outside Europe showed higher primary MET resistance (ORadj = 3.81, 95% CI: 2.25–6.45, P < 0.001). Treatment success in group A reached only 79.8% (568/712) with 7 to 14 days triple therapy tailored to antibiotic susceptibility. Conclusions: Peptic ulcers are rare in dyspeptic H. pylori-infected children. Primary resistance to CLA and MET is markedly dependent on geographical regions of birth and residence. The ongoing survey will show whether implementation of the updated ESPGHAN/NASPGHAN guidelines will improve the eradication success.
What Is Known: Antibiotic susceptibility and treatment adherence are crucial for successful Helicobacter pylori eradication. In 2006, we reported antibiotic resistance in 1233 infected children (1033 treatment-naïve) living in 14 European countries. Primary resistance rates to clarithromycin and metronidazole were 20% and 23%, respectively. What Is New: This second survey in 1333 culture-positive children revealed increasing primary resistance for clarithromycin (25%), but not for metronidazole (21%). Antibiotic resistance significantly depended on geographical regions and migration status, questioning country-based recommendations. Prescribed drug doses were too low, particularly for protein pump inhibitors (PPI). Improved eradication rates can be expected if current European Society of Pediatric Gastroenterology, Hepatology and Nutrition/North American Society of Pediatric Gastroenterology, Hepatology and Nutrition guidelines are followed.

Descrição

Palavras-chave

Abdominal Pain Clarithromycin Endoscopy Helicobacter pylori Metronidazole Pediatric Gastroenterology Peptic Ulcer Disease Infecções Gastrointestinais

Contexto Educativo

Citação

J Pediatr Gastroenterol Nutr. 2020 Oct;71(4):476-483. doi: 10.1097/MPG.0000000000002816.

Projetos de investigação

Unidades organizacionais

Fascículo

Editora

Lippincott, Williams & Wilkins/ European Society for Paediatric Gastroenterology Hepatology and Nutrition

Métricas Alternativas